Outpost24, an innovator in identifying and managing cybersecurity exposure, today announced the results of its 2021 Web Application Security for Healthcare report for the top 10 European pharmaceutical organisations, as ranked by Drugs Discovery and Development based on annual revenue, R&D spend, employee numbers, leadership and more.
Using Outpost24’s external attack surface management tool, the study evaluates the digital footprint of the Top 10 pharmaceutical organisations in the EU by discovering their internet facing web services and scoring the security exposure identified. Nearly 80% of organisations studied were over what Outpost24 considers as ‘critically exposed’ – above 30, indicating a high susceptibility to having security vulnerabilities presented externally for potential exploits. The findings revealed that the top EU pharmaceutical organizations run an exceptionally large amount of web applications compared to other industries, with 3% of them considered suspicious (e.g., test environments that should’ve been removed), and a further 18% using outdated components containing known vulnerabilities.
In the wake of the pandemic, the pharmaceutical and healthcare industry have become “big game” targets for cybercriminals, with by far the highest cost of data breach and prime examples including: COVID-19 vaccine producer, Pfizer/BioNTech, where thousands of sensitive information was leaked, recent targeting of ExecuPharm in March 2020 by nation state TA505 using Clop ransomware and the devastating impact on patients in the Springhill Medical Centre IT system attack.
Outpost24’s latest report examined the unique attack s ..
Support the originator by clicking the read the rest link below.
